Promethera Biosciences SA, which is developing a therapy for liver disease using allogeneic stem cells derived from healthy adult human livers, has raised €23.6 million in a series B financing round that included four corporate investors. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News Regenerative Medicine
